GENFIT (NASDAQ:GNFT) Stock Price Down 3.4% - Should You Sell?

Key Points

• GENFIT S.A. stock price fell by 3.4% during mid-day trading, with shares trading as low as $3.92 before closing at $3.84.
• A new institutional investor, Millennium Management LLC, recently acquired 166,375 shares of GENFIT, representing about 0.33% of the company's total shares.
• GENFIT is actively developing several treatments for metabolic and liver-related diseases, including Elafibranor, which is in Phase III trials for primary biliary cholangitis.

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Get Free Report)'s share price traded down 3.4% on Thursday . The company traded as low as $3.92 and last traded at $3.84. 5,946 shares changed hands during trading, an increase of 134% from the average session volume of 2,546 shares. The stock had previously closed at $3.97.

GENFIT Trading Down 2.9%

The business's fifty day moving average price is $3.98 and its two-hundred day moving average price is $3.82. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.23 and a current ratio of 1.23.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GENFIT stock. OLD Mission Capital LLC bought a new position in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 22,238 shares of the company's stock, valued at approximately $76,000. 2.24% of the stock is currently owned by institutional investors and hedge funds.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.